English | 简体中文 | 繁體中文 | 한국어
Share:
Lubrizol LifeSciences to Showcase Full-Service Medical Device Solutions at MD&M West 2018
Lubrizol LifeSciences to Showcase Full-Service Medical Device Solutions at MD&M West 2018

News Release

Lubrizol LifeSciences to Showcase Full-Service
Medical Device Solutions at MD&M West 2018

CLEVELAND, February 6, 2018 -The Lubrizol Corporation's LifeSciences business will showcase its total solutions capabilities for medical device manufacturers at the MD&M West 2018 Exposition (Booth #2201), February 6-8. Lubrizol LifeSciences is a preferred medical device and pharmaceutical solutions partner, helping customers from concept to commercialization by offering polymer customization, drug-eluting device development and contract manufacturing services. This year, Lubrizol LifeSciences will highlight a strong commitment to the interventional catheters, long-term implant and drug-eluting device markets.

LifeSciences has invested significantly to expand its global development and manufacturing facilities to better serve the growing medical device market by expanding its silicone and thermoplastic capacity with a 71,000-square foot facility.  This facility features enhanced product development capabilities, cellular manufacturing and high-efficiency production lines in Class 7 & 8 clean rooms.

"When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process," states Uwe Winzen, general manager, Lubrizol LifeSciences. "Our long history of polymer expertise and medical device manufacturing, enhanced with recent investments, makes Lubrizol LifeSciences a full-service development partner for the next generation of medical devices, including long-term implantable and drug-eluting device innovations."

Additionally, at MD&M West LifeSciences will highlight a comprehensive suite of services focused on the development of advanced drug/device combination solutions including analytical services for coating characterization, drug release testing and more. LifeSciences is a preferred partner to take a novel device concept and expedite time to market with streamlined product development, clinical and commercial manufacturing capabilities.

About Lubrizol LifeSciences
Lubrizol LifeSciences is a preferred Contract Development and Manufacturing Organization (CDMO) partner for complex pharmaceuticals and high-end medical devices providing differentiated polymers and excipients, along with state-of-the-art design, development and manufacturing services to the healthcare industry.

About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers' success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,300 employees worldwide. Revenues for 2016 were $6.5 billion. For more information, visit Lubrizol.com.

Media Contact
Ben Patti
(216) 447-5827
www.lubrizol.com/LifeSciences

###





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lubrizol via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
NANOBIOTIX signs a 40 M€ non-dilutive financing agreement with the European Investment Bank  
July 27, 2018 00:33 ET
CNH Industrial - 2018 Second Quarter Results  
July 26, 2018 20:33 ET
Iveco Defence Vehicles, shareholder of the Iveco - Oto Melara Consortium (CIO), is awarded a contract to deliver ten Centauro II Armored Vehicles to the Italian Army  
July 25, 2018 04:33 ET
Volta Finance Limited : Net Asset Value(s)  
July 23, 2018 08:00 ET
Kitron to invest in Poland  
July 23, 2018 07:30 ET
BinckBank achieves net profit of € 22.2 million for 18H1 (17H1: € 2.1 million)  
July 23, 2018 07:15 ET
Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke  
July 23, 2018 07:15 ET
Roche receives CE Mark for its Accu-Chek Solo micropump system  
July 23, 2018 07:00 ET
CNH Industrial appoints new Chairman  
July 22, 2018 01:13 ET
CORRECTION: RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2018: SALES AND PROFITABILITY GREW FROM LAST YEAR – STRATEGY EXECUTION SHOWING RESULTS  
July 20, 2018 19:03 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: